Last reviewed · How we verify
BOL-303242-X
BOL-303242-X is a S1P receptor modulator Small molecule drug developed by Bausch & Lomb Incorporated. It is currently in Phase 2 development for Non-infectious uveitis. Also known as: Mapracorat.
BOL-303242-X is a small molecule that targets the S1P1 receptor.
BOL-303242-X is a small molecule glucocorticoid receptor agonist, classified as an agonist. It has been studied for the treatment of conditions including cataract, inflammation, dry eye syndrome, and pain, particularly in the context of cataract surgery.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BOL-303242-X |
|---|---|
| Also known as | Mapracorat |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
By binding to the S1P1 receptor, BOL-303242-X modulates sphingosine-1-phosphate signaling, which plays a crucial role in lymphocyte trafficking and immune response. This mechanism is thought to contribute to its therapeutic effects in treating inflammatory conditions.
Approved indications
- Non-infectious uveitis
Common side effects
- Increased intraocular pressure
Key clinical trials
- Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome (PHASE2)
- Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery (PHASE2)
- Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery (PHASE3)
- Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BOL-303242-X CI brief — competitive landscape report
- BOL-303242-X updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about BOL-303242-X
What is BOL-303242-X?
How does BOL-303242-X work?
What is BOL-303242-X used for?
Who makes BOL-303242-X?
Is BOL-303242-X also known as anything else?
What drug class is BOL-303242-X in?
What development phase is BOL-303242-X in?
What are the side effects of BOL-303242-X?
What does BOL-303242-X target?
Related
- Drug class: All S1P receptor modulator drugs
- Target: All drugs targeting S1P1
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Non-infectious uveitis
- Also known as: Mapracorat
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing